Prophylactic vaccination targeting ERBB3 decreases polyp burden in a mouse model of human colorectal cancer.
Oncoimmunology 2017 7;6(1):e1255395. Epub 2016 Dec 7.
Department of Veterinary Pathobiology, Department of Molecular and Cellular Medicine, Texas A&M University , College Station, TX, USA.
Prophylactic vaccination is typically utilized for the prevention of communicable diseases such as measles and influenza but, with the exception of vaccines to prevent cervical cancer, is not widely used as a means of preventing or reducing the incidence of cancer. Here, we utilize a peptide-based immunotherapeutic approach targeting ERBB3, a pseudo-kinase member of the EGFR/ERBB family of receptor tyrosine kinases, as a means of preventing occurrence of colon polyps. Administration of the peptide resulted in a significant decrease in the development of intestinal polyps in C57BL/6J-Apc(Min) mice, a model of familial adenomatous polyposis (FAP). Read More